IndraLab

Statements

Ponatinib inhibits RIPK1. 12 / 13
1 | 1 11
reach
"Among Abl kinase inhibitors, KW-2449 and Tozasertib [41] only targeted RIPK1, while GNF-7, Ponatinib and DCC-2036 were shown to inhibit both RIPK1 and RIPK3 [33,40,42] ."
33819469
reach
"Ponatinib and pazopanib, which were found could inhibit RIP1 and RIP3, has been approved by Food and Drug Administration (FDA) as chemotherapeutics in clinical treatment [22] ."
37421775
reach
"Interestingly, some US Food and Drug Administration-approved anticancer drugs, including ponatinib and pazopanib, can inhibit RIPK1; these drugs would be better prospects in further clinical studies (Fauster et al., 2015)."
34594225
eidos
"In addition , the activity of RIPK1 , an NSP12 interactor which is associated with apoptosis , necroptosis , and inflammatory pathways , is predicted to be inhibited by ponatinib and pazopanib ."
32444466
reach
"They found that ponatinib can inhibit dual activity of RIPK1 and RIPK3 in vitro, which may limit its clinic application considering the safety."
31011462
reach
"Ponatinib has been shown to inhibit both RIP1 and RIP3 via direct binding [XREF_BIBR, XREF_BIBR]."
28978109
reach
"Two receptor tyrosine kinase inhibitors, Pazopanib and Ponatinib were confirmed to block cell necroptosis by targeting RIPK1, but failed to apply in clinic trails due to cardiotoxicity ( Fauster et al[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
35988837
reach
"This is highlighted by the fact that both ponatinib and sorafenib are also inhibitors of RIPK1, limiting their development as therapies for necroptotic diseases.HTS efforts have also identified other putative type I and II RIPK3 inhibitor scaffolds (Figure 13)."
36781172
reach
"Furthermore, ponatinib and pazopanib are expected to suppress the activity of receptor-interacting serine/threonine protein kinase 1 (RIPK1), a SARS-CoV-2 NSP12 interactor linked to apoptosis, necroptosis, and inflammatory processes [167]."
36252792
reach
"Leveraging this similarity, they explored the RIPK1 inhibitory activity of a range of ABL kinase inhibitors and confirmed that ponatinib efficiently inhibited RIPK1, consistent with Superti-Furga G's [MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
38199165
reach
"Ponatinib inhibits RIPK1 (38) and RIPK3 (39) and is a US Food and Drug Administration-approved drug for the treatment of acute lymphoid leukemia and chronic myeloid leukemia."
37708272
reach
"Ponatinib and DCC-2036 were shown to inhibit both RIPK1 and RIPK3 [30,32] , while Tozasertib only targeted RIPK1 to inhibit necroptosis [45] ."
32247850